These studies have evaluated the effect of CB2 agonists on breast cancer models and shown a reduction in the size of breast cancer tumors (Hanlon et al., 2016; Elbaz et al., 2017; Zhang et al., 2018). This evidence concerns the gene CNR2 and breast carcinoma.